diabetes mellitus type 2 (DM type II)
Conditions
Interventions
An open, parallel, cluster randomised, controlled trial among DM2 patients from general practices, with a HbA1c of above 7.0% , who are using maximal oral antidiabetic agents and are eligible for insu
Sponsors
VU Universtity Medical Center, EMGO institute
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes mellitus from general practices 2. Age between 35 and 75 years 3. HbA1c > 7.0% in combination with maximal oral antidiabetic agents (i.e. the combination of two oral medicines, what cannot further be increased) 4. Capable of using a computer and the internet 5. Willingness to accept, and ability to inject insulin glargine (Lantus®) 6. Ability and willingness to perform self monitoring of blood glucose 7. Written informed consent 8. Understanding of Dutch language
Exclusion criteria
Exclusion criteria: 1. Serious mental impairment 2. Serious endocrine disorders 3. Serious disease with a life expectancy < 1 year 4. Corticosteroid use 5. Not capable to use a computer or not used to the internet.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between intervention and control groups in glycaemic control measured by glycated haemoglobin concentration (HbA1c-level) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Treatment satisfaction 2. Quality of life 3. Self-efficacy 4. Illness perceptions 5. Patient-reported number of hypoglycaemias 6. Weight gain 7. Total required insulin dose 8. Time delay to reach stable insulin dose 9. Changes in lipid spectrum 10. (Oral) medication changes 11. Frequency of contact with health care providers 12. Frequency of log-ins on the site and use of different pages of the site | — |
Contacts
Public ContactM.G.A. Roek
EMGO Instituut VU Medisch Centrum van der Boechorststraat 7
Outcome results
None listed